Apyx Medical Corporation (APYX)
NASDAQ:APYX
Earnings Data
Report Date
May 07, 2026After Close (Confirmed)
Period Ending
2026 (Q1)Consensus EPS Forecast
-0.11Last Year’s EPS
-0.1Same Quarter Last Year
Strong Buy
Based on 3 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Positive
The call highlights strong commercialization progress for AYON, record quarterly revenue (+35% YoY), improved adjusted EBITDA (positive in Q4), materially reduced cash burn and a healthy cash balance, plus constructive 2026 guidance emphasizing continued Surgical Aesthetics growth. Offsets include a planned reduction in OEM revenue, modest margin contraction, remaining net loss, pending regulatory clearance for a key AYON handpiece (mid-2026) that is excluded from guidance, and limited current international availability. Overall the positives (record sales, improved profitability metrics, cash runway, clear growth plan) outweigh the execution and timing risks described.Company Guidance
Record Quarterly Revenue
Total revenue for Q4 2025 was $19.2M versus $14.2M in Q4 2024, a 35% year-over-year increase, driven primarily by the AYON commercial launch.
Surgical Aesthetics Surge Driven by AYON
Surgical Aesthetics revenue grew 38% year-over-year to $16.7M in Q4 2025 (from $12.1M), with domestic Surgical Aesthetics up nearly 50% year-over-year, largely attributable to AYON system sales and increased single-use handpiece volume.
Successful AYON Launch and Positive Market Reception
AYON completed its first full commercial quarter after launch in September 2025. The product generated strong preorders and early-adopter feedback, list price cited at ~$360,000, and management reports demand exceeding expectations across key metrics.
Regulatory Progress and Potential Upside
A follow-up 510(k) for AYON label expansion (power-assisted liposuction) was submitted in Q4 2025, with productive FDA interactions and an anticipated clearance in mid-2026; upon clearance the feature can be activated on systems in the field and additional handpieces can be sold (identified as upside to current guidance).
Profitability and Margin Improvements (Non-GAAP)
Gross profit in Q4 2025 rose to $12.0M (gross margin 62.6%), and adjusted EBITDA turned positive at $0.7M in Q4 2025 versus an adjusted EBITDA loss of $2.2M in Q4 2024.
Operating Results Improved vs Prior Year
Income from operations was $11k in Q4 2025 compared with an operating loss of $3.0M in Q4 2024. Net loss attributable to stockholders narrowed to $1.3M ($0.03 per share) versus $4.6M ($0.12 per share) in Q4 2024.
Reduced Cash Burn and Strong Cash Position
Cash used in operating activities for FY 2025 was $8.0M versus $18.7M in FY 2024. Cash and cash equivalents were $31.7M at December 31, 2025. Management expects cash runway through 2027 and plans to be cash-flow positive by Q4 2026.
Sustained Cost Reductions and Lower Operating Expenses
Total operating expenses for 2025 were $39.5M, down from $48.2M in 2024 and $53.7M in 2023, reflecting prior restructuring and cost-control measures.
2026 Guidance Reflects Continued Growth
Company guided 2026 revenue to $57.5M–$58.5M (approximately +9% to +11% vs FY 2025) with Surgical Aesthetics revenue expected at $53M–$54M (+17% to +19%). Management expects full-year gross margins of ~61%–62% and operating expenses not to exceed $45M.
APYX Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
APYX Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
Mar 10, 2026 | $3.43 | $3.45 | +0.58% |
Nov 06, 2025 | $3.14 | $3.35 | +6.69% |
Aug 07, 2025 | $1.96 | $2.18 | +11.22% |
May 08, 2025 | $1.25 | $1.18 | -5.60% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Apyx Medical Corporation (APYX) report earnings?
Apyx Medical Corporation (APYX) is schdueled to report earning on May 07, 2026, After Close (Confirmed).
What is Apyx Medical Corporation (APYX) earnings time?
Apyx Medical Corporation (APYX) earnings time is at May 07, 2026, After Close (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is APYX EPS forecast?
APYX EPS forecast for the fiscal quarter 2026 (Q1) is -0.11.